Díaz, T., Rodríguez, V., Lozano, E., Mena, M., Calderón, M., Rosiñol, L., . . . de Larrea, C. F. (2017). The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica.
Chicago ZitierstilDíaz, Tania, et al. "The BET Bromodomain Inhibitor CPI203 Improves Lenalidomide and Dexamethasone Activity in in Vitro and in Vivo Models of Multiple Myeloma By Blockade of Ikaros and MYC Signaling." Haematologica 2017.
MLA ZitierstilDíaz, Tania, et al. "The BET Bromodomain Inhibitor CPI203 Improves Lenalidomide and Dexamethasone Activity in in Vitro and in Vivo Models of Multiple Myeloma By Blockade of Ikaros and MYC Signaling." Haematologica 2017.